WO1990014835A1 - Method to treat rheumatoid arthritis - Google Patents
Method to treat rheumatoid arthritis Download PDFInfo
- Publication number
- WO1990014835A1 WO1990014835A1 PCT/US1990/003038 US9003038W WO9014835A1 WO 1990014835 A1 WO1990014835 A1 WO 1990014835A1 US 9003038 W US9003038 W US 9003038W WO 9014835 A1 WO9014835 A1 WO 9014835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- cells
- sequence
- raa
- class
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 75
- 230000002163 immunogen Effects 0.000 claims abstract description 12
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 9
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 7
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 5
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 5
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 10
- 230000001861 immunosuppressant effect Effects 0.000 claims description 10
- 239000003018 immunosuppressive agent Substances 0.000 claims description 10
- 229960001438 immunostimulant agent Drugs 0.000 claims description 9
- 239000003022 immunostimulating agent Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 108010091858 peptide Q Proteins 0.000 abstract description 3
- 238000002255 vaccination Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 102000054766 genetic haplotypes Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 4
- 108010022208 HLA-Dw4 antigen Proteins 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000003618 borate buffered saline Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- WAAXYLYXYLKHJZ-UHFFFAOYSA-N 1-[3-(1-hydroxy-2,5-dioxopyrrolidine-3-carbonyl)phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 WAAXYLYXYLKHJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
Definitions
- the invention relates to regulation of the im ⁇ mune system to prevent and treat autoimmune diseases . More specifically, it concerns procedures to prevent and treat the immune response which is characteristic of rheumatoid arthritis in humans.
- the B-lymphocytes and acrophages from more than 90% of patients with seropositive rheumatoid arthritis express the Class II HLA protein DR4 or DRl, as defined serologically. It has been shown that DR4 specificity is present on several different haplotypes, three of which, Dw4 , Dwl4 and Dwl5, are associated with the B-lymphocytes and macrophages from rheumatoid arthritis patients, and two of which, DwlO and Dwl3, are not.
- the B-lympho- cytes and macrophages of subjects with rheumatoid arthritis express the Class II haplotypes Dw4, Dwl4, Dwl5 or DRl.
- RA rheumatoid arthritis
- the sequence of the region is either QKRAA (Dw4) or QRRAA (Dwl4, Dwl5 and DRl).
- R arginine
- K lysine
- the sequence Q(K/R)RAA may be important in the development and symptoms of rheumatoid arthritis.
- MHC major histocompatibility complex
- the Class II protein contains a site capable of binding the foreign antigen (or a fragment thereof) and another site which recognizes a T-cell receptor. Structural studies by others have indicated that the position on the Class II MHC protein on which the Q(K/R)RAA sequence is located corresponds to the T-cell receptor recognition site.
- Rheumatoid arthritis is thought to be an autoimmune disease wherein certain protein components of the synovial fluid are recognized as foreign by the immune system. Presumably they are presented to the T- lymphocytes in the context of an MHC Class II protein, which MHC Class II carrier is recognized as self by the T- lymphocyte. Based on the foregoing paragraphs, it may be supposed that this self-recognition site includes Q(K/ R)RAA. It has now been found that by administering a suitable vaccine, the response of T-lymphocytes to the synovial fluid-associated antigen can be either diverted from the helper T-cell class, or prevented. The vaccines of the invention thus prevent T-helper proliferation in response to the synovial antigen conjugated to the Class II recognition site Q(K/R)RAA.
- the invention provides vaccines for the preven- tion and treatment of the autoimmune response to synovial protein which manifests itself in the symptoms of rheumatoid arthritis.
- the vaccines of the invention ef ⁇ fectively prevent the T-helper cell response to these proteins presented in the context of the MHC Class II histocompatibility protein having the sequence Q(K/R)RAA at its recognition site.
- the invention is directed to a method to immunize a subject to prevent or ameliorate rheumatoid arthritis
- the vaccination protocol comprises administration of an effective amount of the peptide Q(K/R)RAA in immunogenic form in conjunction with an effective amount of one or more immunostimulatory or immunosuppresant substances which preferentially enhance the proliferation of suppressor and/or cytotoxic T-cells, and/or suppress the expansion of helper T-cells without effect on suppressor/cytotoxic expansion.
- im unoaffecting substances include interleukin-6 (IL-6), cyclosporin A, antibodies against CD4 antigen, transforming growth factor-beta (TGF-beta), and combinations thereof.
- the invention is also directed to vaccines useful in this method.
- the invention is directed to a vaccine useful in preventing rheumatoid arthritis, which vaccine comprises the Q(K/R)RAA a ino acid sequence coupled to an invariant portion of a Class I histocompatibility sequence, and to methods of rheumatoid arthritis prevention and amelioration using this vaccine.
- Figure 1 shows the stimulation (or not) of T- cells derived from EBV-exposed and EBV-nonexposed subjects by gpllO and by Dw4 peptide.
- Figure 2 shows antibody titers measured against gpllO peptide or protein of a rabbit immunized with gpllO peptide.
- Figure 3 shows immunoblots of HLA Class II Dw4 and Dw2 proteins with rabbit anti-D 4 antisera.
- Figure 4 shows the comparative amino acid sequences of Dw4, Dwl4 and DwlO beta peptides.
- the vaccines of the invention utilize as an es ⁇ sential component the amino acid sequence Q(K/R)RAA in an immunogenic form or an immunogenic form of the peptide sequence which forms that portion of a T-cell receptor binding to this epitope.
- the specific peptide hapte ⁇ sequence may be part of a larger polypeptide or protein and/or may be conjugated, option ⁇ ally through a linker, to a carrier.
- peptides are included within a larger protein
- convenient larger proteins include additional amino acid residues found in the Class II DR-beta-1 chain or additional amino acid residues adjacent this peptide in glycoprotein gpllO as ⁇ sociated with the Epstein-Barr virus; for peptides representing the Q(K/R)RAA sequence in the context of the Class I MHC protein constant regions, extensions of these regions may also be employed.
- the individual peptide may also be used. In both cases arbitrary, non- interfering chain extensions may also be employed.
- Suitable carriers which enhance immun ⁇ genicity of the hapten, or confer immunogenicity upon it include the commonly employed keyhole limpet hemocyanin (KLH) protein, tetanus toxoid, or other antigenically neutral materials, such as human serum albumin. If a separate carrier such as tetanus toxoid, KLH or HSA, is used, the peptide may be conjugated to the carrier using means standard in the art, including the use of linkers, many of which are commercially available from Pierce Chemical Company, Rockf ⁇ rd, IL. Typical linkers include, for example, SMCC and SPDP. Methods of effecting such conjugation are well known.
- the vaccines of the invention are administered to persons at risk for rheumatoid arthritis as shown by the haplotypes described above.
- individuals with haplotypes corresponding to Dw4, Dwl4, Dwl5 or DRl are administered the vaccine.
- the immunogenic form of Q(K/R)RAA is administered in conjunction with an immunostimulant and/or immunosuppressant which results in a preferential expan- sion if T-suppressor and/or cyctotoxic cells at the expense of T-helper cells.
- an immunostimulant and/or immunosuppressant which results in a preferential expan- sion if T-suppressor and/or cyctotoxic cells at the expense of T-helper cells.
- stimulants which expand suppressor/cytotoxic populations but which do not affect helper populations may be used; or substances which actively suppress helper populations, but do not affect suppressor/cytotoxic T-cells may be used, or combinations of these factors may be used.
- Certain substances which effect this differential expansion are known in the art; however, the invention includes the use of any substance which can be shown to have this effect.
- Interleukin-6 is an appropriate immunostimulant for suppressor/cytotoxic T- cells. It is often desirable to include IL-2 to enhance this stimulation as well. Cyclosporin A, TGF-beta, and anti-CD4 antibodies (see, e.g., Carteron, N.L., et al. , J Immunol (1988) 140:713-716) are appropriate helper cell inhibitors.
- administered “in conjunction with” is meant that either administration is in the same vaccine formula ⁇ tion (containing both the immunogenic form of Q(K/R)RAA and the immunostimulant and/or immunosuppressant) or each of these components may be administered within a conjunc ⁇ tive period of time so that their cooperative effect is obtained. Suitable conjunctive time periods are of the order of 4 hours to 2 days, preferably 4 hours to 1 day.
- the immunostimulant/immunosuppressant and the immunogenic peptide may be administered in any order, and protocols of repeated administrations of each or both can also be employed.
- Suitable routes of administration are systemic, and include administration by injection such as intra ⁇ venous, intramuscular, peritoneal, or subcutaneous injec- tion. Subcutaneous or intramuscular administration are preferred.
- the immunogenic peptide and immunostimulatory/ immunosuppressant substance are formulated for injection using standard formulations for the administration of peptides which include suitable excipients such as buff- ers, Ringer's solution, or Hank's solution, and may further include wetting agents, stabilizers, and the like. Suitable adjuvants may also be included.
- Other forms of administration such as transmembrane or transdermal administration using formulations suitable for these routes may also be employed. A wide range of formulations is found, for example, in Remington's Pharmaceutical Sci ⁇ ences, latest edition, Mack Publishing Company, Easton, Pennsylvania.
- Suitable amounts of the immunogenic peptide are about 100 ug-100 mg per patient, preferably 10-100 mg.
- the immunostimulant/immunosuppressant or combination should be administered in an amount according to the potency of the substance chosen; for IL-6, for example, suitable dosage ranges are 1-100 ug/kg, preferably 20-50 ug/kg. It is understood, of course, that dosage level is highly dependent on the particular immunogenic form of the peptide used, the i ⁇ vmunostimulant/immunosuppressant selected, the route of administration selected, the nature of the formulation, and the individual response of the subject. Establishment of optimum dosage protocols and regimens for a subject, taking account of the foregoing parameters, is routinely done and is well within ordinary skill.
- the peptide Q(K/ R)RAA or a larger peptide containing this sequence is coupled to an invariant portion of a Class I histocompatibility sequence to generate the active component of the vaccine.
- the invariant portion of Class I histocompatibility sequences are known and the relevant data are deposited in Genbank and other equivalent data- bases generally known in the art. (See referenced art in Chimini, G., et al. , J Exp Med (1989) 169:297-302. )
- EBV Epstein-Barr virus
- Dwl4/Dwl5/DR1 KDLLEQRRAAVDTYC
- gpllO QENQEQKRAAQRAAGC
- DwlO KDILEDERAAVDTYC.
- peptides were used as test stimulating peptides for T-cell proliferation or were conjugated to KLH using m-maleimidobenzoyl-n-hydroxysuccinimide as described by Green, N., Cell (1982) ⁇ :477-487; Liu, F.T., et al., Biochemistry (1979) __ :690-697, for use in im ⁇ munization.
- Example 2 Sensitization of T-Cells to Q(K/R)RAA Stimulation by Prior Exposure to EBV
- the peptides synthesized in Example 2 were used to determine the response of T-cells in vitro as follows: The method was a modification of that disclosed in Ford, D., Cell Immunol (1983) 7_9:334-344; Thorley-Lawson, D.A. , et al., Proc Natl Acad Sci USA (1987) ⁇ 4:5384-5388, both incorporated herein by reference.
- peripheral blood mononuclear cells were obtained both from a donor with no history of EBV infection, as indicated by the absence of antibody to the viral capsid antigen (VCA) and from an otherwise normal subject with a high titer of anti-VCA antibodies, indicating prior exposure to EBV.
- the mononuclear cells were isolated by isopycnic centrifugation through Ficoll-Hypaque, and were washed three times in RPMI-1640 medium.
- the cells were then suspended at a density of 10 cells/ml in the same medium supplemented with 10% pooled human AB serum, 1% L- glut-amine, 100 U/ml penicillin, and 100 ug/ml streptomycin in the presence of 1 ug/ml of a stimulatory peptide selected from the list above.
- a sample of 10 cells were taken from the bulk culture to evaluate the primary proliferative response.
- the remaining cells were counted and serially diluted in fresh medium sup- plemented with the same peptide to be tested, or without said peptide as a control.
- the cells were then distributed in 100 ul aliquots containing 50,000, 25,000, 10,000, or 5,000 viable cells from the primary culture in 96-well round-bottom culture plates and the number of cells in each well adjusted to 10 by the addition of ir ⁇ radiated (3,000 rad) peripheral blood mononuclear cells from the same donor. For each cell density, 18 wells with peptide and 6 control wells without peptide were assayed. After 4 days of this secondary culture, 1 uCi of tritiated thymidine was added to each well 18 hours before cell harvesting on glass fiber filters. For each cell dilution, positive wells were defined as having cpm higher than (mean + 2 standard deviations) of the cpm obtained for 6 control wells. Frequency of precursor T-cells was evaluated by plotting the percentage of negative wells for each dilution against the number of cells per well, as described by Ford et al. (supra) ⁇
- Panels a and c show the response (in cpm/well) at various dilutions of cells derived from a VCA-positive donor; panels b and d, from VCA-negative donors. Panels a and b were treated with the gpllO peptide; panels c and d, with the Dw4 peptide.
- RA-Susceptible Haplotype Antibodies The peptides prepared in Example 2 and conjugated to KLH were used to raise antibodies in rab ⁇ bits. New Zealand white rabbits were injected subcutane- ously with 1 mg of the conjugate emulsified in complete Freund's adjuvant, and then boosted three times at 3 week intervals with 1 mg of conjugate in incomplete Freund's adjuvant. The rabbits were bled four days after the last injection and sera were stored at -20 C.
- Antibody titers of the resulting sera were tested using an ELISA assay or by i munoblot.
- the ELISA assay was by the procedure of Luka, J. , et al., J Immunol Methods (1984) 7_:145-156, incorporated herein by refer ⁇ ence. Briefly, the antigen peptide was used to coat ELISA plates, and various solutions of preimmune or immune rab- bit sera, diluted in isotonic borate-buffered saline (BBS) were added in 100-ul aliquots to the wells and incubated overnight at 4°C.
- BBS isotonic borate-buffered saline
- ELISA determinations were made when reactivity of antibodies was tested to EBV gpllO.
- the gpllO was purified by affinity chromatography from P3HR1 lymphoblasts according to the method of Kishishita, M. , et al., Virology (1984) 133:393-395.
- the epitope recognized on the gpllO protein was that of the peptide, since a 20-fold dilution of serum preincubated with 100 ug/ml of gpllO peptide was no longer capable of binding gpllO protein.
- a membrane extract from 2 x 10 cells was loaded into each lane of a 10% polyacrylamide gel containing 0.1% sodium dodecylsiilfate and 1 mM 2-mercaptoethanol. After electrophoresis, the reduced and denatured membrane polypeptides were electrophoretically transferred to nitrocellulose sheets, as described by Towbin, H. , et al. , Proc Natl Acad Sci USA (1979) 7_6:4350-4354; Billings, P.B., et al., ibid (1983) ⁇ 0:7104-7108.
- the filters were then preincubated for one hour in a solution containing 0.05 M borate, 0.15 M NaCl, pH 3, and 3% powdered milk, followed by overnight incubation at 4°C with the antisera diluted at the same dilution.
- candidate peptides were added to the antibody solu- tions prior to their incubation with the nitrocellulose sheets.
- borate buffer After extensive washing of the sheets with borate buffer, bound antibody was detected using 125I- protein A (1 mCi/ l, ICN, Irvine, CA) .
- the sheets were incubated for 1 hour with the detecting reagent, washed with BBS, dried, and exposed to Kodak XAR film overnight at -70 C using an intensifier screen.
- the ability of Dw4 peptide to raise specific antibodies was also shown by assay of the rabbit antiserum by immunoblot as described above. The results of this assay are shown in Figure 3.
- the immunoblot in panel A is a control testing anti-DR-beta monoclonal antibody diluted 1:1000 with extracts from Molt 4 (M4) cells, HLA Dw4 homozygous lymphoblastoid cells (D4), or HLA Dw2 homozygous lymphoblastoid cells (D2). Both DR beta proteins react, M4 does not.
- M4 Molt 4
- D4 HLA Dw4 homozygous lymphoblastoid cells
- D2 HLA Dw2 homozygous lymphoblastoid cells
- Lane set 1 represents the results when the electrophoresis was run using the membrane extracts alone. Only the D4 extract is immunoreactive with the antibody, confirming the specificity of the antiserum.
- Lane set 2 shows the results when the antiserum was preincubated with 10 ug/ml Dw4 peptide; the binding to the membrane-derived D4 peptide in the gel is completely eliminated.
- Lane set 3 shows the results when the antiserum was preincubated with the 100 ug/ml of the control peptide DwlO. No effect on the binding of the antibody to the D4 extract was noted.
- Lane set 4 shows that preincubation with the related peptide Dwl4 at 10 ug/ml was partially effective in eliminating binding to D4; the binding was almost eliminated when the concentration of Dwl4 was increased to 100 ug/ml (lane set 5).
- gpllO protein The recognition of gpllO protein was inhibited by preincubation of a 100-fold dilution of the serum with either 100 ug/ml gpllO peptide or 100 ug/ml Dw4 peptide.
- the recognition of gpllO peptide was inhibited by preincubation with 10 ug/ml of either Dw4 or Dw4' peptide (Example 2) .
- peptides are conjugated using dicyclohexylcarbodiimide to the peptide of the sequence Q(K/R)RAA and formulated into vaccines.
- the gene encoding the desired portion of the above peptides with extensions of the residues Q(K/R)RAA are constructed and inserted into standard recombinant expression systems for production of fusion proteins. The resulting fusions are then formulated into vaccines as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002056450A CA2056450A1 (en) | 1989-05-31 | 1990-05-31 | Method to treat rheumatoid arthritis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35978289A | 1989-05-31 | 1989-05-31 | |
US359,782 | 1994-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990014835A1 true WO1990014835A1 (en) | 1990-12-13 |
Family
ID=23415246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/003038 WO1990014835A1 (en) | 1989-05-31 | 1990-05-31 | Method to treat rheumatoid arthritis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0474764A4 (en) |
JP (1) | JPH05500653A (en) |
CA (1) | CA2056450A1 (en) |
WO (1) | WO1990014835A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0423201A1 (en) * | 1988-06-23 | 1991-04-24 | Biospan Corp | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity. |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
EP0661996A1 (en) * | 1991-11-19 | 1995-07-12 | Anergen, Inc. | Mhc subunit conjugates useful in ameliorating deleterious immune responses |
EP0667781A1 (en) * | 1992-08-31 | 1995-08-23 | Board Of Regents Of The University Of Oklahoma | Peptide diagnostics and therapeutics for spondyloarthropathies |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
WO1995031984A1 (en) * | 1994-05-20 | 1995-11-30 | The Regents Of The University Of California | Method and reagents for the treatment of rheumatoid arthritis |
WO1997034002A1 (en) * | 1996-03-15 | 1997-09-18 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
US6106840A (en) * | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US6682731B1 (en) * | 1994-03-24 | 2004-01-27 | Ludwig Institute For Cancer Research | Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules |
WO2004104026A1 (en) * | 2003-05-21 | 2004-12-02 | Biotech Tools S.A. | Peptide complex |
US6946132B2 (en) * | 1994-05-20 | 2005-09-20 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
US6989146B2 (en) | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
US7074893B2 (en) | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
US7301005B2 (en) | 2000-11-01 | 2007-11-27 | Salvatore Albani | Immunomodulatory peptides derived from heat shock proteins and uses thereof |
US7608683B2 (en) | 2000-08-09 | 2009-10-27 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
US8436136B2 (en) | 2003-05-21 | 2013-05-07 | Biotech Tools S.A. | Peptide complex |
US20140212444A1 (en) * | 2010-06-16 | 2014-07-31 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2004744B (en) * | 1977-09-28 | 1982-05-26 | Sanderson A R | Immonulogical preparations |
US4400376A (en) * | 1979-03-27 | 1983-08-23 | National Research Development Corporation | Immunological preparations |
CA1327162C (en) * | 1987-04-09 | 1994-02-22 | Board Of Trustees Of The Leland Stanford Junior University (The) | Method for prophylactically treating an individual for an autoimmune disease |
-
1990
- 1990-05-31 WO PCT/US1990/003038 patent/WO1990014835A1/en not_active Application Discontinuation
- 1990-05-31 JP JP2508822A patent/JPH05500653A/en active Pending
- 1990-05-31 CA CA002056450A patent/CA2056450A1/en not_active Abandoned
- 1990-05-31 EP EP19900909247 patent/EP0474764A4/en not_active Withdrawn
Non-Patent Citations (8)
Title |
---|
CHEMICAL ABSTRACT, Vol. 108, issued 1988, The Shared Epitope Hypothesis. An Approach to Understanding the Molecular Genetics of Susceptibility to Rheumatoid Arthritis", (GREGERSEN), Abstract No. 107138b, Arthritis Rheum., 1987, 30(11), 1205-13, See the Abstract. * |
Clin. Exp. Immunol. Vol. 70, issued 1987, "Synovial Fluid Mononuclear Cells Exhibit a Spontaneous HLA-DR Drive Proliferative Response", (DUKE), Biosis Abstract No. 06436059, See the Abstract. * |
Journal Clinical Invest., Vol. 77, Issued March 1986, "Shared T Cell Recognition Sites on Human Histocompatibility Leukocyte Antigen Class II Molecules of Patients with Seropositive Rheumatoid Arthritis", (GORONZY et al.) pages 1042-49, See pages 1042, 1046-49. * |
Journal Immunol., Vol. 139, No.5, issued 01 September 1987, "Inhibition of The Helper Function of Murine T Cells With Fab'-Anti-L3T4 Ricin A Chain Immunotoxin1", (STREET et al.), pages 1734-38, See page 1734. * |
Journal Immunol., Vol. 141, issued 15 September 1988, "Effects of Anti-Lyt-2 and Anti-L3T4 Monoclonal Antibodies on The Function of Cytotoxic T Lymphocyte/Helper T Lymphocyte Hybrid T Cell Clones", (HAVRAN et al.), Pages 1808-12, See page 1808. * |
Journal Immunol., Vol. 141, No. 5, issued 01 September 1988, "IL-6/bsf-2 Functions As a Killer Helper Factor In the In Vitro Induction of Cytotoxic T Cells", (OKADA et al.), Pages 1543-49, See page 1543. * |
Journal of Immunology, Vol. 140, No. 2, issued January 1988, "Identification of the DRw10 DRbeta1-Chain Allele As Encoding A Polymorphic Class II Major Histocompatibility Complex Epitope Otherwise Restricted to DRbeta2 Molecules of The DRw53 Type", (MATSUYAMA et al.), pages 537-43, See pages 537 and 541-42. * |
See also references of EP0474764A4 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106840A (en) * | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
EP0423201A4 (en) * | 1988-06-23 | 1992-10-14 | Biospan Corporation | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
US5284935A (en) * | 1988-06-23 | 1994-02-08 | Anergen, Inc. | MHC-mediated toxic conjugates useful in ameliorating autoimmunity |
US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
US6451314B1 (en) | 1988-06-23 | 2002-09-17 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
EP0423201A1 (en) * | 1988-06-23 | 1991-04-24 | Biospan Corp | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity. |
EP0661996A1 (en) * | 1991-11-19 | 1995-07-12 | Anergen, Inc. | Mhc subunit conjugates useful in ameliorating deleterious immune responses |
EP0661996A4 (en) * | 1991-11-19 | 1997-05-21 | Anergen Inc | Mhc subunit conjugates useful in ameliorating deleterious immune responses. |
EP0667781A1 (en) * | 1992-08-31 | 1995-08-23 | Board Of Regents Of The University Of Oklahoma | Peptide diagnostics and therapeutics for spondyloarthropathies |
EP0667781A4 (en) * | 1992-08-31 | 1997-07-16 | Univ Oklahoma | Peptide diagnostics and therapeutics for spondyloarthropathies. |
US6682731B1 (en) * | 1994-03-24 | 2004-01-27 | Ludwig Institute For Cancer Research | Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules |
US6153200A (en) * | 1994-05-20 | 2000-11-28 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
US5773570A (en) * | 1994-05-20 | 1998-06-30 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
WO1995031984A1 (en) * | 1994-05-20 | 1995-11-30 | The Regents Of The University Of California | Method and reagents for the treatment of rheumatoid arthritis |
AU696646B2 (en) * | 1994-05-20 | 1998-09-17 | Regents Of The University Of California, The | Method and reagents for the treatment of rheumatoid arthritis |
US6946132B2 (en) * | 1994-05-20 | 2005-09-20 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
US7094597B1 (en) | 1994-05-20 | 2006-08-22 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
WO1997034002A1 (en) * | 1996-03-15 | 1997-09-18 | The Regents Of The University Of California | Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
EP1939295A1 (en) | 1996-03-15 | 2008-07-02 | The Regents of the University of California | Vaccine compostions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
US7608683B2 (en) | 2000-08-09 | 2009-10-27 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
US6989146B2 (en) | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
US7301005B2 (en) | 2000-11-01 | 2007-11-27 | Salvatore Albani | Immunomodulatory peptides derived from heat shock proteins and uses thereof |
US7074893B2 (en) | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
WO2004104026A1 (en) * | 2003-05-21 | 2004-12-02 | Biotech Tools S.A. | Peptide complex |
US8436136B2 (en) | 2003-05-21 | 2013-05-07 | Biotech Tools S.A. | Peptide complex |
US20140212444A1 (en) * | 2010-06-16 | 2014-07-31 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
US9555086B2 (en) * | 2010-06-16 | 2017-01-31 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
EP3463482A4 (en) * | 2016-06-07 | 2020-01-15 | The Brigham and Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
US11534496B2 (en) | 2016-06-07 | 2022-12-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions |
Also Published As
Publication number | Publication date |
---|---|
EP0474764A4 (en) | 1992-11-19 |
EP0474764A1 (en) | 1992-03-18 |
CA2056450A1 (en) | 1990-12-01 |
JPH05500653A (en) | 1993-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8110203B2 (en) | Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes | |
WO1990014835A1 (en) | Method to treat rheumatoid arthritis | |
US6265539B1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
US20030003440A1 (en) | Novel CCR5 epitope and antibodies against it | |
EP0339504A2 (en) | Human immunodeficiency virus (HIV) env-coded peptide capable of eliciting HIV-inhibiting antibodies in mammals | |
JP2006056893A (en) | Compound synthetic peptide structure that induces counteractive antibody and cytotoxic t lymphocyte to hiv | |
US9266928B2 (en) | Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction | |
US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
JPH07506810A (en) | Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes that are self-antigens | |
Wahren et al. | Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160 | |
US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
Golding et al. | Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion | |
SALMON-CÉRON et al. | Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers | |
Brander et al. | Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL) | |
EP0750636A1 (en) | Methods to diagnose and treat hiv-1 infection | |
Weijer et al. | Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene | |
Gokulan et al. | Bioactive Fragment of Human IL‐1β [163‐171] Modulates the Immune Response to Synthetic Peptides of HIV | |
AU2006200454B2 (en) | Compositions and methods for treating viral infections | |
US6290963B1 (en) | Anti-HIV compositions containing native and recombinant peptides | |
EP0328390B1 (en) | Peptide treatment of refractory infectious diseases | |
KR19980702834A (en) | Nontoxic immunogens derived from retroviral regulatory proteins, antibodies, methods for their preparation, and pharmaceutical compositions containing them | |
VASLIN et al. | Nef and Gag synthetic peptide priming of antibody responses to HIV type 1 antigens in mice and primates | |
AU694204C (en) | Methods to diagnose and treat HIV-1 infection | |
Koff | The prospects for AIDS vaccines | |
Benveniste et al. | Four cross-linked HIV Gag peptides prime the immune response to HIV proteins in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2056450 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990909247 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990909247 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990909247 Country of ref document: EP |